ZFSW
Cancer vaccine developer
ZFSW, founded in July, 1995 and headquartered in Chongqing, is an anti-cancer vaccine developer. The founder is Jiang Rensheng. Listed on the SZSE on September 28, 2010, the company's major shareholders are Jiang Rensheng, Jiang Lingfeng and Wu Guanjiang. Rivals that have direct and indirect competition with ZFSW include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
Shenzhen textile A: the order of line 7 is full, and the production line speed is climbing
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Half day main capital net inflow of power equipment, non bank finance, selling banks, etc
SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year
EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.
Jun 06, 2024 06:18 PM
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
Monitoring of main funds of star mine: Top 10 list of early trading
Pharmaceutical and biological stocks fell sharply in early trading
US Senate committee to investigate the role of cryptocurrency in cyber crime
A breakthrough in cell therapy of solid tumor by Zhifei biological joint stock company